Courier Capital LLC Makes New $210,000 Investment in Kenvue Inc. (NYSE:KVUE)

Courier Capital LLC bought a new position in shares of Kenvue Inc. (NYSE:KVUE) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 8,777 shares of the company’s stock, valued at approximately $210,000.

Other large investors also recently bought and sold shares of the company. Fulton Bank N.A. boosted its holdings in shares of Kenvue by 0.6% in the 1st quarter. Fulton Bank N.A. now owns 78,888 shares of the company’s stock valued at $1,892,000 after acquiring an additional 465 shares during the last quarter. Principle Wealth Partners LLC boosted its holdings in shares of Kenvue by 3.7% in the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock valued at $303,000 after acquiring an additional 500 shares during the last quarter. White Pine Capital LLC boosted its holdings in shares of Kenvue by 1.0% in the 4th quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock valued at $1,165,000 after acquiring an additional 542 shares during the last quarter. Deseret Mutual Benefit Administrators boosted its holdings in shares of Kenvue by 29.0% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock valued at $54,000 after acquiring an additional 568 shares during the last quarter. Finally, SRS Capital Advisors Inc. boosted its holdings in shares of Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after acquiring an additional 571 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

NYSE:KVUE opened at $21.51 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a fifty day moving average of $23.07 and a two-hundred day moving average of $22.55. The stock has a market capitalization of $41.26 billion, a PE ratio of 40.58, a P/E/G ratio of 2.62 and a beta of 0.98. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $25.17.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. The company had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The firm’s revenue for the quarter was down 3.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.28 earnings per share. As a group, research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.81%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue’s dividend payout ratio is presently 149.09%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on KVUE. Redburn Atlantic began coverage on shares of Kenvue in a report on Thursday, April 10th. They issued a “neutral” rating and a $23.50 price objective on the stock. Citigroup boosted their target price on shares of Kenvue from $22.00 to $24.50 and gave the company a “neutral” rating in a research note on Friday, May 9th. Canaccord Genuity Group boosted their target price on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Piper Sandler boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. Finally, Barclays boosted their target price on shares of Kenvue from $22.00 to $23.00 and gave the company an “equal weight” rating in a research note on Monday, May 12th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.